Announced
Completed
Financials
Tags
Acquisition
United States
Private
Majority
Single Bidder
Pharmaceuticals
Domestic
drug discovery
Friendly
Completed
Synopsis
Cortexyme, a clinical-stage biopharmaceutical company, completed the acquisition of Novosteo, a developer of a drug discovery platform, for $120m. "The acquisition of Novosteo adds a highly promising set of assets and meaningfully expands the breadth of our management team. On behalf of Cortexyme’s Board, I would like to thank Chris Lowe for his leadership as interim CEO and guiding us through this acquisition," David Lamond, Cortexyme Chairman of Board of Directors.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.